Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): An open-label, randomised, phase 2 trial

Darrell White

doi:10.1016/S0140-6736(15)01120-4

Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): An open-label, randomised, phase 2 trial

Darrell White

Engineering

科研成果: 期刊稿件 › 文章 › 同行评审

729 引用（Scopus）

源语言	英语
页（从-至）	1551-1560
页数	10
期刊	The Lancet
卷	387
期	10027
DOI	https://doi.org/10.1016/S0140-6736(15)01120-4
出版状态	已出版 - 4月 9 2016

!!!ASJC Scopus Subject Areas

一般医学

访问文件

10.1016/S0140-6736(15)01120-4

其它文件与链接

引用此

@article{05518c7d04ad4eae9c9e90e7bc83c9c9,

title = "Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): An open-label, randomised, phase 2 trial",

author = "Darrell White",

year = "2016",

month = apr,

day = "9",

doi = "10.1016/S0140-6736(15)01120-4",

language = "English",

volume = "387",

pages = "1551--1560",

journal = "The Lancet",

issn = "0140-6736",

publisher = "Elsevier Limited",

number = "10027",

}

TY - JOUR

T1 - Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS)

T2 - An open-label, randomised, phase 2 trial

AU - White, Darrell

PY - 2016/4/9

Y1 - 2016/4/9

UR - http://www.scopus.com/inward/record.url?scp=84953325096&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84953325096&partnerID=8YFLogxK

U2 - 10.1016/S0140-6736(15)01120-4

DO - 10.1016/S0140-6736(15)01120-4

M3 - Article

C2 - 26778538

AN - SCOPUS:84953325096

SN - 0140-6736

VL - 387

SP - 1551

EP - 1560

JO - The Lancet

JF - The Lancet

IS - 10027

ER -

Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): An open-label, randomised, phase 2 trial

!!!ASJC Scopus Subject Areas

访问文件

其它文件与链接

指纹

引用此